 BOCA RATON, Fla., July 22, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of 0.55 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 27, 2021, subject to satisfaction of customary closing conditions. 